Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin

Despite the clinical efficacy of anthracycline agents such as doxorubicin, dose-limiting cardiac toxicities significantly limit their long-term use. Here, we present the case of a 33-year-old female patient with extensive metastatic ER+/PR+/HER2– mucinous adenocarcinoma of the breast, who was starte...

Descripción completa

Detalles Bibliográficos
Autores principales: Shee, Kevin, Kono, Alan T., D'Anna, Susan P., Seltzer, Mark A., Lu, Xiaoying, Miller, Todd W., Chamberlin, Mary D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216250/
https://www.ncbi.nlm.nih.gov/pubmed/28101033
http://dx.doi.org/10.1159/000453608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216250/
https://www.ncbi.nlm.nih.gov/pubmed/28101033
http://dx.doi.org/10.1159/000453608

Ejemplares similares